腹腔内灌注贝伐珠单抗和氟尿嘧啶治疗结直肠癌恶性腹水的临床研究  

The clinical study of intraperitoneal injection bevacizumab plus fluorouraci in treatment of malignant ascites of colorectal cancer

作　　者：李翔[1] LI Xiang(3th Department of Medical Oncology,Jiangxi Province Cancer Hospital,Nanchang 330029,China.)

机构地区：[1]江西省肿瘤医院内三科,南昌330029

出　　处：《江西医药》2018年第1期11-14,17,共5页Jiangxi Medical Journal

基　　金：江西省卫生计划生育委员会;课题编号20155487

摘　　要：目的观察不同剂量贝伐珠单抗联合腹腔化疗治疗结直肠癌恶性腹水患者的近期疗效,探索贝伐珠单抗的最佳治疗剂量。方法将45例结直肠癌恶性腹水患者随机分为三组,每组15例;单纯5-Fu灌注组(对照组),低剂量贝伐珠单抗(3mg/kg)联合5-Fu灌注1组(治疗1组),高剂量贝伐珠单抗(5mg/kg)联合5-Fu灌注2组(治疗2组),三组所有患者均行常规FOLFOX6方案化疗。结果对照组、治疗1、2组有效率分别为40.0%、80.0%、86.7%,治疗1、2组有效率均高于对照组,差异有统计学意义(P<0.05);治疗1、2组间有效率无显著差异(P>0.05)。三组VEGF水平均较治疗前明显下降,差异有统计学意义(P<0.05),治疗1、2组下降水平均较对照组明显,差异均有统计学意义(P<0.05),治疗1、2组间差异无统计学意义(P>0.05)。45例患者对治疗耐受良好,无严重不良反应发生。结论腹腔内灌注贝伐珠单抗联合腹腔化疗优于单纯腹腔化疗,并且低剂量贝伐珠单抗的疗效与高剂量方案相当,成本更低,值得临床进一步研究论证。Objective To observe the recent effect and safety of different doses of intraperitoneal injection bevacizumab plus fluorouraci in treatment of colorectal cancer associated with malignant ascites,and to explore the optimal therapeutic dose of bevacizumab.Methods 45 patients with colorectal cancer associated with malignant ascites were randomly divided into three groups,each group also included 15 cases.Intraperitoneal injection fluorouraci alone group(control group),Intraperitoneal injection low doses of bevacizumab(3mg/Kg)plus fluorouraci(experiment 1 group),Intraperitoneal injection high doses of bevacizumab(5mg/Kg)plus fluorouraci(experiment 2 group).All three groups were treated by FOLFOX6 regimen.Results The effective rates of control group,experiment 1 group and experiment 2 group were 40.0%,80.0%and 86.7%,respectively.The effective rates of control group were significantly less than the experiment 1 group and experiment 2 group(P<0.05).There were no significant differences in the effective rates between experiment 1 group and experiment 2 group(P>0.05.After treatment,VEGF level in ascites of three groups were lower than that of three groups before treatment(P<0.05).The decrease of experiment 1 group and experiment 2 group were significantly higher than that of control group(P<0.05).There were no differences in the decrease between experiment 1 group and experiment 2 group(P>0.05).All the patients were of good tolerance in whole therapy and no severe side effects occured.Conclusion Intraperitoneal injection bevacizumab plus fluorouraci in treatment of colorectal cancer associated with malignant ascites is superior to Intraperitoneal injection fluorouraci alone.In addition,Intraperitoneal injection low doses of bevacizumab is similar to high doses of bevacizumab,and it has low cost.

关 键 词：结直肠癌 恶性腹水 贝伐珠单抗 腹腔灌注化疗 

分 类 号：R735.3[医药卫生—肿瘤]